A retrospective study investigating pretreatment prognostic factors and early markers for outcomes in advanced melanoma patients treated with nivolumab
Latest Information Update: 06 Dec 2016
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 06 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress